Sandoz Ranluspec Biosimilar to Lucentis Approved by European Commission
Tuesday, February 24, 2026
On February 23, 2026, Sandoz announced a significant milestone in the European biosimilars market with the European Commission's approval of Ranluspec®, a biosimilar referencing Genentech's Lucentis® (ranibizumab). This approval, highlighted in Pearce IP's BioBlast® report for the week ending February 20, 2026, but dated February 23, positions Sandoz and its partner Lupin as key players in expanding access to affordable biologic therapies for retinal diseases across the EU.
Ranluspec targets neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and other retinal conditions previously dominated by the originator product. Lucentis, a monoclonal antibody fragment inhibiting vascular endothelial growth factor (VEGF), has been a blockbuster since its 2007 launch, generating billions in sales. Biosimilars like Ranluspec are critical for reducing treatment costs, which can exceed €10,000 per patient annually, thereby enhancing healthcare sustainability amid rising demand from aging populations.
The approval follows rigorous regulatory review under the European Medicines Agency (EMA) pathway for biosimilars, demonstrating similarity in quality, safety, and efficacy through comparative clinical studies, pharmacokinetics, and immunogenicity assessments. Sandoz's track record in biosimilars, with over 20 approvals globally, underscores its manufacturing expertise at facilities compliant with EU Good Manufacturing Practices (GMP). This launch aligns with the EU's push for generics and biosimilars under the Pharma Package reforms, aiming to balance innovation incentives with affordability.
Market analysts project biosimilars capturing 60-70% of the ranibizumab market within three years post-entry, driven by payer preferences and hospital tendering. Lupin's involvement leverages its R&D strengths in complex injectables, potentially accelerating commercialization. This development bolsters Europe's biosimilars ecosystem, supporting Strategy category goals by fostering competition and investment in biomanufacturing.
Broader implications include pressure on originators to innovate while enabling patient access. Sandoz plans a phased rollout starting Q2 2026, targeting high-volume markets like Germany and France. Industry experts view this as a catalyst for further ophthalmic biosimilars, addressing a €2.5 billion EU segment. Regulatory changes, such as simplified MDR pathways, indirectly support supply chain robustness for these cold-chain biologics.
In the context of EU Biotech Act proposals, such approvals exemplify risk-proportionate regulation enhancing competitiveness. Sandoz's expansion in Europe reflects strategic investments in capacity, with new fill-finish lines in Kundl, Austria. This approval coincides with coalition efforts like the European Life Sciences Coalition to mobilize €24 billion in VC for scale-ups.
Challenges remain, including physician adoption and anti-VEGF market dynamics, but data from prior biosimilars like Byooviz show 30% uptake within months. Sandoz's pharmacovigilance commitments ensure post-marketing safety. This event reinforces Europe's leadership in biosimilars, projected to save €20 billion annually by 2025 per IQVIA. Stakeholders anticipate accelerated R&D in next-gen ophthalmics, integrating digital health for personalized dosing.
Ultimately, Ranluspec's approval advances Clinical Trials and Biotechnology categories by validating interchangeability, influencing generics policies. It signals a maturing EU market ready for complex biologics, with implications for supply chain innovations in pharma equipment for sterile injectables. As executives strategize, this underscores the need for agile partnerships in a reform-driven landscape.
